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Introduction
Apoptosis or suicide-programmed cell death is
observed both in physiological and pathological condi-
tions. The process plays an important role in the mon-
itoring of cell count during maturation and functions to
remove damaged or cancer cells. Apoptosis is associ-
ated with the mitochondria or post-mitochondrial path-
way and occurs when cell death signals begin to pre-
dominate over the signals that maintain cell life. FasL
molecule binding to the specific Fas receptor found on
the cell surface is one of the activation signals of the
post-mitochondrial pathway [1].
The Fas ligand is a 40-kD type I membrane glyco-
protein and a member of the tumor necrosis factor (TNF)
family. It can be found on activated T lymphocytes and
NK (natural killer) cells [2,3]. The Fas protein is a spe-
cific receptor for FasL (also called CD95 or APO-1) and
a 40-kD type II membrane glycoprotein homologous to
TNF. This protein occurs on various types of normal
cells, e.g.: in the thymus, lungs, intestines, spleen,
prostate or uterus [2,4]. The Fas receptor upon binding to
the FasL activates its death domain (DD) and thus trig-
gers a series of caspases [3,6-8], which results in cells
death. The Fas system is responsible for cytotoxic T cell-
mediated apoptosis and plays a major role in the mainte-
nance of immunological homeostasis [5]. This process is
impaired in neoplastic disease as cancer cells prevent
apoptosis. The involvement of these proteins has been
described in such malignancies as tumors of the breast
[6], lungs [7], esophagus [8] or stomach [9]. 
Due to the fact that colorectal carcinoma is one of
the most common malignancies both in women and
men, especially those over 50 years of age, the objec-
tive of the current study was to assess the expression
of FasL and FasR in colorectal carcinoma, and to
investigate the relationship between their expression
and chosen clinicopathological parameters. 
Materials and methods
Tissue samples. The study group consisted of 50 patients with col-
orectal carcinoma, operated on in the Surgical Department of the 
J. Sniadecki Hospital in Bialystok. Colorectal carcinoma specimens
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and 17 control samples of normal colorectal mucosa were exam-
ined. Sections, 4 µm-thick, were cut from paraffin blocks and
stained with hematoxylin and eosin (H+E). The routine histopatho-
logical assessment of the sections referred to the histological type,
malignancy grade (G), clinico-pathological pTN status, regional
lymph node involvement, presence of distant metastases, lympho-
cytic infiltration, vascular invasion and tumor budding. Inflamma-
tory lymphocytic infiltration was graded as: 0 – lack, 1 – weak, dif-
fused, 2 – moderate, 3 – strong, lymphocyte nests according to the
Jass classification [10]. Lymphatic and venous invasions were
examined, and assessed together as vascular invasion as in Guzins-
ka-Ustymowicz article [11].
Immunohistochemical analysis. Formalin-fixed and paraffin-
embedded tissue specimens were cut on a microtome into 4 µm sec-
tions. The sections were deparaffinized in xylenes and hydrated in
alcohols. To visualize the antigen, the sections were heated in a
microwave oven for 15 min in a citrate buffer (pH 6.0). They were
incubated with 3% hydrogen peroxide solution in order to block
endogenous peroxidase. Next, incubation was performed with
mouse monoclonal antibody against human Fas (Sc-8009, Santa
Cruz Biotechnology) over the night at 4°C and with goat polyclonal
antibody against human FasL (Sc-834-G, Santa Cruz Biotechnolo-
gy). The reaction was carried out using biotinylated anti-mouse anti-
body and streptavidin-conjugated with horseradish peroxidase
(LSAB2, DAKO, Poland). A colour reaction for peroxidase was
developed with chromogene DAB (DAKO, Poland). Fas and FasL
expressions were determined using the semiquantitative method and
assessed as strong (reaction visible in ≥25% of tumour cells) and
weak (lack of reaction or the reaction present in <25% of cancer
cells). Positive reactions were calculated in at least 500 cancer cells
in each tissue specimen under a light microscope (×400). 
Statistical analysis. Statistical analysis was conducted using Spear-
man's correlation coefficient test. A p-value of <0.05 was considered
statistically significant. Missing data were removed in pairs. 
Results
Fas and FasL expression in normal mucosa
and colorectal adenocarcinoma
The expression of Fas receptor was observed on the
cell membrane whereas FasL was present in the cyto-
plasm of the glandular epithelial cells in the control
samples and in the colorectal carcinoma cells (Fig. 1).
Among the 50 patients with colorectal carcinoma, the
histochemical reaction for FasR was found to be weak
in 75.5% and strong in 24.5% of cases. In the control
group, with normal glandular epithelium, the expres-
sion of Fas was strong in 100% of cases. However, the
expression of FasL in colorectal cancer patients was
found to be weak in 30% and strong in 70% of the
study cases, but absent in the control group (Fig. 2).
Moreover, over 50% of the lymphocytes present in the
inflammatory infiltration accompanying the tumor
showed strong FasR expression (Fig. 3).
Relationship between Fas and clinico-
-pathological parameters
Statistical analysis showed no correlations of Fas pro-
tein expression in the main mass of tumor with
patients' age, gender, tumor location, histological type,
pT stage, lymph node involvement, presence of distant
metastases, inflammatory lymphocytic infiltration,
vascular invasion or tumor budding (Table 1).
Relationship between FasL and clinico-patho-
logical parameters.
No correlation was also noted of FasL expression with
patients' age or gender, tumor location, histological
type, pT stage, lymph node involvement, presence of
distant metastases, inflammatory lymphocytic infiltra-
tion or tumor budding. However, the strong FasL
expression was observed to correlate statistically sig-
nificantly with the presence of vascular invasion
(p=0.005) (Table 1).
Discussion
Apoptosis is an extremely important phenomenon in the
development and life of organisms, ensuring removal of
unnecessary and even potentially dangerous cells, with
impaired genetic (DNA) information. However, cancer
cells escape the mechanism and tend to proliferate in an
uncontrolled way. We observed a marked increase in
FasL protein expression and a drop in Fas receptor in
colorectal cancer cells as compared to normal glandular
cells in the colon. These observations seem to be con-
sistent with the findings reported by other authors. Bel-
luco et al [12] presented the results in which FasL
expression showed a linear correlation with cancer pro-
gression from hyperplastic polyps to advanced colorec-
tal carcinoma (pT4). Zhu et al. [13] also observed high
FasL expression in 84.9% of colorectal cancers as com-
pared to normal glandular epithelium (3.75%), and
lower Fas receptor expression in 43.4% of colorectal
cancer cases than in normal epithelium (73.3%). Thus,
low expression of Fas receptor in cancer cells may sug-
gest that the Fas/FasL pathway inducing apoptosis in
these cells was reduced or eliminated. 
Moreover, we observed Fas/FasL positive lympho-
cytes. Their presence in the vicinity of neoplastic infil-
tration and the presence of high FasL expression in can-
cer cells seem to reflect the defense mechanism of can-
cer cells against anticancer immune cells. This was sug-
gested by Okada [14] and Zhu [13], who investigated
apoptosis in tumor-infiltrating lymphocytes (TILs).
They demonstrated that apoptosis in TILs increased with
higher expression of FasL protein in colorectal cancer
cells. Thus, cancer cells produce Fas ligand in the
defense against Fas-positive lymphocytes by inducing
apoptosis in them. In this way, they defend themselves
against the immune response of the organism and there-
fore escape death that would come from the immune
cells. This defense mechanism of cancer cells allows
tumor growth in local tissue or even in distant organs.
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Since significant changes have been demonstrated
in the expressions of Fas and FasL proteins and their
role in the defense of cancer cells has been considered,
we could expect them to play a major part in patients'
prognosis. However, in our study the expressions of
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Fig. 1. Immunohistochemical staining. Cytoplasmic Fas receptor expression in normal mucosa (A) and colorectal cancer (B) and FasL
protein expression in normal mucosa (C) and colorectal cancer (D) (original magnification ×400).
Fig. 2. Patterns of Fas and FasL expression in 17 normal mucosa
specimens and 50 colorectal adenocarcinomas.
Fig. 3. Strong Fas receptor expression visible in normal glandular
epithelium of the colon and in grade 3 lymphatic infiltration. Lack
of reaction in cancer cells of the colon (original magnification
×400).
Fas and FasL proteins showed no correlation with any
of the important clinicopathological parameters, such
as histological type, pT stage or the presence of local
lymph node involvement or distant metastases. Other
researchers observed a correlation between FasL over-
production and metastasizing. Okada et al. [14] noted
that FasL protein expression may be associated with
local lymph node involvement. Moreover, Zhang et al.
[15] observed positive expression of FasL protein in
all metastases of colorectal carcinoma to the liver;
FasL was found to correlate statistically significantly
with metastases to the liver and lymph nodes. Yokomi-
zo et al. [16] revealed that FasL protein expression can
serve as a prognostic factor for metastases to the liver
in colorectal carcinomas with vascular invasion. Like-
wise, in our study, the occurrence of cancer embolism
in blood and lymphatic vessels appeared to be statisti-
cally significant in patients with strong expression of
FasL protein (85.6% of cases), whereas low expression
was present only in 14.3% of patients. This may indi-
cate FasL protein involvement in cancer progression.
Nozoe et al. [17] not only observed FasL correlation
with metastases to lymph nodes and distant organs, but
also with Dukes' classification, superficial tumor type,
depth of infiltration and lymphatic permeation of the
colorectal carcinoma, but not with vascular invasion.
In other studies, the expression of FasL protein was
found to correlate with histological type [18,19], high
level of microsatellite instability (MSI-H) [18,20] and
patients' survival [19]. 
Similarly to our studies, many authors also found
no correlations between the respective clinico-
histopathological parameters, such as histological dif-
ferentiation grade [14,15,18-21], Dukes' classification
[14,20], tumor histological type [20] and location
[14,17,19,20], depth of infiltration [15] and the pres-
ence of local lymph node involvement or distant
metastases [19]. It would be interesting to consider
whether the changes in FasL protein and Fas receptor
expression would be useful prognostic factors for col-
orectal carcinoma patients. Different researchers show
divergent results for the correlation between the pro-
tein expression and clinicopathological parameters of
the tumor. Undoubtedly, however, these proteins could
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Table 1. Relationship between Fas and FasL expression in primary lesion of colorectal cancer and clinicopathological factors. Relation-
ship is significant at the level of p<0.05. Significant relationship is marked in bold.
become good therapeutic targets in colorectal carcino-
ma since their expression differs distinctly between
normal intestinal epithelium and cancer cells, and
known is the mechanism by which cancer cells escape
death due to the apoptosis-inducing Fas/FasL pathway
disorders. 
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